Dermatitis Atopic Publications (22629)

Search

Dermatitis Atopic Publications

2016Jan
J Immunol Res
J Immunol Res 2016 21;2016:8163803. Epub 2016 Dec 21.
Biochemistry Unit, Biomedicine Department, Faculty of Medicine, University of Barcelona, Casanova 143, 08036 Barcelona, Spain.

IgE is an immunoglobulin that plays a central role in acute allergic reactions and chronic inflammatory allergic diseases. The development of a drug able to neutralize this antibody represents a breakthrough in the treatment of inflammatory pathologies with a probable allergic basis. This review focuses on IgE-related chronic diseases, such as allergic asthma and chronic urticaria (CU), and on the role of the anti-IgE monoclonal antibody, omalizumab, in their treatment. Read More

We also assess the off-label use of omalizumab for other pathologies associated with IgE and report the latest findings concerning this drug and other new related drugs. To date, omalizumab has only been approved for severe allergic asthma and unresponsive chronic urticaria treatments. In allergic asthma, omalizumab has demonstrated its efficacy in reducing the dose of inhaled corticosteroids required by patients, decreasing the number of asthma exacerbations, and limiting the effect on airway remodeling. In CU, omalizumab treatment rapidly improves symptoms and in some cases achieves complete disease remission. In systemic mastocytosis, omalizumab also improves symptoms and its prophylactic use to prevent anaphylactic reactions has also been discussed. In other pathologies such as atopic dermatitis, food allergy, allergic rhinitis, nasal polyposis, and keratoconjunctivitis, omalizumab significantly improves clinical manifestations. Omalizumab acts in two ways: by sequestering free IgE and by accelerating the dissociation of the IgE-Fcε receptor I complex.

2017Jan
Proc. Natl. Acad. Sci. U.S.A.
Proc Natl Acad Sci U S A 2017 Jan 17. Epub 2017 Jan 17.
Department of Immune Regulation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, Japan

Th2 immunity plays important roles in both protective and allergic responses. Nevertheless, the nature of antigen-presenting cells responsible for Th2 cell differentiation remains ill-defined compared with the nature of the cells responsible for Th1 and Th17 cell differentiation. Basophils have attracted attention as a producer of Th2-inducing cytokine IL-4, whereas their MHC class II (MHC-II) expression and function as antigen-presenting cells are matters of considerable controversy. Read More

Here we revisited the MHC-II expression on basophils and explored its functional relevance in Th2 cell differentiation. Basophils generated in vitro from bone marrow cells in culture with IL-3 plus GM-CSF displayed MHC-II on the cell surface, whereas those generated in culture with IL-3 alone did not. Of note, these MHC-II-expressing basophils showed little or no transcription of the corresponding MHC-II gene. The GM-CSF addition to culture expanded dendritic cells (DCs) other than basophils. Coculture of basophils and DCs revealed that basophils acquired peptide-MHC-II complexes from DCs via cell contact-dependent trogocytosis. The acquired complexes, together with CD86, enabled basophils to stimulate peptide-specific T cells, leading to their proliferation and IL-4 production, indicating that basophils can function as antigen-presenting cells for Th2 cell differentiation. Transfer of MHC-II from DCs to basophils was also detected in draining lymph nodes of mice with atopic dermatitis-like skin inflammation. Thus, the present study defined the mechanism by which basophils display MHC-II on the cell surface and appears to reconcile some discrepancies observed in previous studies.

2017Feb
Contact Derm.
Contact Dermatitis 2017 Feb;76(2):119-120
Department of Dermatology and the Allergy Centre, Odense University Hospital, 5000, Odense C, Denmark.

Atopic dermatitis (AD) is characterized by impaired epidermal barrier with increased transepidermal water loss (TEWL). Scratching further compromises skin integrity, contributing to a cycle of inflammation. The objective of the present study was to investigate a topical anti-itch foam in improving skin barrier and itch. Read More


A single center open study was performed on 26 adults previously diagnosed with AD but without active lesions. One leg was treated with a single application of an anti-itch foam. Dryness, scaling, roughness, cracking, and signs of scratching were assessed before, 6, and 24 hours after application. Skin hydration was measured at 24 hours. The same product was applied twice daily for 7.5 days to the other leg, and skin hydration and TEWL were measured at baseline and on days 2, 8, and 10. Pruritus was assessed by volunteers and by a dermatologist.
A significant increase in skin moisture (P less than 0.001) was measured 6 hours after a single application. Scores of dryness, scaling, roughness (P less than 0.001) and cracking (P=0.002) were significantly improved up to 24 hours after a single application. After a 7.5-day repeated application period, the anti-itch foam significantly reduced TEWL (P less than 0.001) compared to baseline. Skin hydration significantly improved (P less than 0.001) in the same time period. 48 hours after the last application, these improvements remained significant (P less than 0.001).
The anti-itch foam improved the skin barrier. It provided immediate relief of clinical signs of AD including pruritus. Moreover, it delivered a long-lasting moisturizing effect, comforting the skin, and improving overall skin condition. J Drugs Dermatol. 2016;15(suppl 11):s77-80..

2017Jan
BMJ Open
BMJ Open 2017 Jan 16;7(1):e013637. Epub 2017 Jan 16.
Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, UK.

Asthma is one of the most frequently diagnosed respiratory diseases in the UK, and commonly co-occurs with other respiratory and allergic diseases, such as chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Previous studies have shown an increased risk of lung cancer related to asthma, but the evidence is mixed when accounting for co-occurring respiratory diseases and allergic conditions. A systematic review of published data that investigate the relationship between asthma and lung cancer, accounting for co-occurring respiratory and allergic diseases, will be conducted to investigate the independent association of asthma with lung cancer. Read More


A systematic review will be conducted, and include original reports of cohort, cross-sectional and case-control studies of the association of asthma with lung cancer after accounting for co-occurring respiratory diseases. Articles published up to June 2016 will be included, and their selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A standardised data extraction form will be developed and pretested, and descriptive analyses will be used to summarise the available literature. If appropriate, pooled effect estimates of the association between asthma and lung cancer, given adjustment for a specific co-occurring condition will be estimated using random effects models. Potential sources of heterogeneity and between study heterogeneity will also be investigated.
The study will be a review of published data and does not require ethical approval. Results will be disseminated through a peer-reviewed publication.
International Prospective Register for Systematic Reviews (PROSPERO) number CRD42016043341.

2017Jan
Int. J. Biol. Macromol.
Int J Biol Macromol 2017 Jan 13. Epub 2017 Jan 13.
Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati 781039, Assam, India. Electronic address:
2017Jan
J Dermatolog Treat
J Dermatolog Treat 2017 Jan 16:1-53. Epub 2017 Jan 16.
a Dermatology Department , Royal Victoria Infirmary , Newcastle Upon Tyne.

Prescribing for pregnant or lactating patients and male patients wishing to father children can be a difficult area for dermatologists. There is a lack of review articles of commonly used systemic medications in dermatology with respect to their effects on developing embryogenesis and their potential transfer across the placenta, in breast milk and in seminal fluid. This paper aims to provide an up to date summary of evidence to better equip dermatologists to inform patients about the effects of systemic medications commonly used in dermatology to treat conditions such as atopic dermatitis, psoriasis and acne, on current and future embryogenesis and fertility. Read More


We have provided detailed evidence about the safety profile for the use of systemic medication used in the treatment of common dermatological conditions, such as atopic dermatitis, psoriasis and acne with respect to pregnancy, breastfeeding and spermatogenesis. The following medications are completely contraindicated in pregnancy: retinoids, methotrexate, mycophenolate and fumaric acid esters, whilst ciclosporin and hydroxychloroquine are considered safer options. Azathioprine and biologics have been considered on a case by case scenario. There is an association with impaired neonatal immunity and a possible VACTERL association with biologics. There is insufficient evidence to recommend ustekinumab. Dapsone should also be considered on a case by case basis as it is associated with haemolysis and hyperbilirubinaemia in the neonate. The following medications are contraindicated in breastfeeding: retinoids, methotrexate, mycophenolate, fumaric acid esters and ciclosporin. There is conflicting information about the use of azathioprine. Dapsone use during breastfeeding is associated with haemolysis and hyperbilirubinaemia in the neonate. The use of hydroxychloroquine is felt to be safe. The data associated with the use of biologic agents is limited, specific guidance for each biological medication is detailed in the relevant section. Methotrexate is completely contraindicated in male patients actively trying for children and needs to be suspended for at least 3 months prior to contraception. The following medications are felt to be low risk: biologics, ciclopsorin and retinoids, there are some concerns however regarding isotretinoin use in males when their female partner is already pregnant and recent advice recommends contraception. There is insufficient information regarding the use of mycophenolate, fumaric acid esters, azathioprine, hydroxychloroquine, dapsone and ustekinumab in order to consider their safety profile.

2016Jan
Vopr Kurortol Fizioter Lech Fiz Kult
Vopr Kurortol Fizioter Lech Fiz Kult 2016 ;93(6):21-26
Nauchno-proizvodstvennaja kompanija 'Lechebnyj klimat', Chajkovskij, Rossija.

Salt therapy (halotherapy) as a non-traditional method for the treatment of various pathological conditions has become an increasingly popular therapeutic modality in Russia and abroad. The Perm region houses one of the largest sylvinite-bearing potash deposits in the world. These salts are possessed of special physical and chemical properties of great value for the treatment of different diseases. Read More

The objective of the present work was to develop novel approaches to the application of sylvinite for the treatment and prevention of various diseases.
The subjects of investigations were the modern sylvinite constructions of different types. The study included a total of 195 patients who were randomly divided into two groups. The main group consisted of 50 patients presenting with allergic respiratory diseases, 20 ones with atopic dermatitis, and 21 with vulgar psoriasis. 31 patients had undergone aortocoronary bypass surgery in the preceding period. 49 pregnant women presented with a complicated course of pregnancy. 24 patients suffered from chronic generalized catarrhal gingivitis. The control group was comprised of 188 persons presenting with the same diseases (46, 30, 18, 20, 49, 25 patients in each of the above groups respectively) who received only the traditional pharmacotherapeutic treatment. All the patients underwent evaluation of the respiratory and cardiovascular functions. The clinical manifestations and the skin damage areas were estimated in the patients with atopic dermatitis and vulgar psoriasis. Blood circulation in placenta, the state of the periodontal tissues, and local immunity in the oral cavity mucosa, as well as the subjective psychological status were evaluated. The physical and chemical characteristics of the internal environment of the salt constructions (microclimatic factors, radiation, air ionization, salt aerosol content) were estimated.
The data obtained provided a basis for the development and patenting of the methods for the treatment of atopic dermatitis, vulgar psoriasis, placental insufficiency, and chronic generalized catarrhal gingivitis based on the halotherapeutic modalities.
The results of the long-term hygienic, physical and clinical investigations made it possible to identify the complex of curative factors inherent in the natural mineral sylvinite constructions. These factors are believed to create the optimal conditions for the efficient management of the patients presenting with dermatological, cardiological, obstetrical, and stomatological problems.

2017Jan
Vet. Dermatol.
Vet Dermatol 2017 Jan 16. Epub 2017 Jan 16.
Genclis SA, 15 rue du Bois de la Champelle, 54500, Vandœuvre-lès-Nancy, France.

Food allergy is often suspected in dogs with clinical signs of atopic dermatitis. This diagnosis is confirmed with an elimination diet and a subsequent challenge with regular food. Laboratory tests for the diagnosis of food allergy in dogs are unreliable and/or technically difficult. Read More

Cyno-DIAL(®) is a Western blot method that might assist with the selection of an appropriate elimination diet.
To evaluate the performance of Cyno-DIAL(®) for the selection of an elimination diet and diagnosis of food allergy.
Thirty eight dogs with atopic dermatitis completed an elimination diet. Combining the results of the diet trials and the challenges, 14 dogs were classified as food allergic (FA), 22 as nonfood-allergic and two as ambiguous cases.
Amongst all dogs and amongst dogs with a clinical diagnosis of FA, 3% and 7% (respectively) were positive to Royal Canin Anallergenic(®) , Vet-Concept Kanguru(®) or Vet-Concept Dog Sana(®) ; 8% and 7% to Hill's d/d Duck and Rice(®) ; 8% and 21% to Hill's z/d Ultra Allergen Free(®) ; 53% and 64% to Eukanuba Dermatosis FP(®) ; and 32% and 43% to a home-cooked diet of horse meat, potatoes and zucchini. The specificity and sensitivity of Cyno-DIAL(®) for diagnosing food allergy were 73% and 71%, respectively.
Although Cyno-DIAL(®) was considered potentially useful for identifying appropriate foods for elimination diet trials, it cannot be recommended for the diagnosis of food allergy. The Cyno-DIAL(®) test performed better than some previously evaluated ELISA-based tests.